Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis

Clinical Cancer Research

Volumn 2, Issue 7, 1996, Pages 1177-1184

  Seshadri, Ram ^a   Lee, Christine S L ^c   Hui, Rina ^c   McCaul, Kieran ^b   Horsfall, David J ^a   Sutherland, Robert L ^c  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b South Australian Health Commission   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; PROGESTERONE RECEPTOR; CYCLIN D1; ESTROGEN RECEPTOR; FGF3 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 3; ONCOPROTEIN;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER SURVIVAL; CHROMOSOME 11Q; DISEASE ASSOCIATION; EARLY DIAGNOSIS; GENE AMPLIFICATION; GENE LOCUS; HUMAN; HUMAN TISSUE; ONCOGENE; PREDICTION; PRIORITY JOURNAL; RELAPSE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; ADULT; AGED; BREAST TUMOR; CHROMOSOME 11; FEMALE; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 11; CYCLIN D1; FEMALE; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTORS; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTORS, ESTROGEN;

EID: 0029657594     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. McGuire, W. L. Breast cancer prognostic factors: evaluation guidelines J. Natl. Cancer Inst., 83: 154-155, 1991.
2. Osborne, C. K. Prognostic factors for breast cancer: have they met their promise? J. Clin. Oncol., 10: 679-682, 1992.
3. Galea, M. H., Blamey, R. W., Elston, C. E., and Ellis, I. O. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res. Treat., 22: 207-219, 1992.
4. Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V., and Kitchen, P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin. Oncol., 11: 1936-1942, 1993.
5. Seshadri, R., Horsfall, D. J., Firgaira, F., McCaul, K., Setlur, V., Chalmers, A. H., Yeo, R., Ingram, D., Dawkins, H., and Hahnel, R. The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in primary breast cancer. Int J Cancer., 56: 61-65, 1994.
6. Seshadri, R., Leong, A. S., McCaul, K., Firgaira, F. A., Setlur, V., and Horsfall, D. J. Relationship between p53 gene abnormalities and other tumor characteristics in breast cancer prognosis. Int. J. Cancer, 69: 135-141, 1996.
7. Peters, G., Brookes, S., Smith, R., and Dickson, C. Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell, 33: 369-377, 1983.
8. Peters, G., Brookes, S., Smith, R., Placzek, M., and Dickson, C. The mouse homolog of the hst/k-FGF gene is adjacent to int-2 and is activated by proviral insertion in some virally induced mammary tumors. Proc. Natl. Acad. Sci. USA, 86: 5678-5682, 1989.
9. Lidereau, R., Callahan, R., Dickson, C., Peters, G., Escot, C., and Ali, I. U. Amplification of the int-2 gene in primary human breast tumors. Oncogene Res., 2: 285-291, 1988.
10. Fantl, V., Smith, R., Brookes, S., Dickson, C., and Peters, G. Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv., 18: 77-94, 1993.
11. Schuuring, E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes. Gene, 159: 83-96, 1995.
12. Dickson, C., Fantl, V., Gillett, C., Brookes, S., Bartek, J., Smith, R., Fisher, C., Barnes, D., and Peters, G. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett., 90: 43-50, 1995.
13. Zhou, D. J., Casey, G., and Cline, M. J. Amplification of human int-2 in breast cancers and squamous carcinomas. Oncogene, 2: 279-282, 1988.
14. Machotka, S. V., Garrett, C. T., Schwartz, A. M., and Callahan, R. Amplification of the proto-oncogenes int-2, c-erbB2, and c-myc in human breast cancer Clin. Chim. Acta, 184: 207-217, 1989.
15. Buckley, M. F., Sweeney, K. J., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K., Musgrove, E. A., and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127-2133, 1993.
16. Gillett, C., Fantl, V., Smith, R., Fisher, C., Bartek, J., Dickson, C., Barnes, D., and Peters, G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining Cancer Res., 54: 1812-1817, 1994
17. Bartkova, J., Lukas, J., Muller, H., Lutzhoft, D., Strauss, M., and Bartek, J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer, 57: 353-361, 1994.
18. Bartkova, J., Lukas, J., Strauss, M., and Bartek, J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene, 10: 775-778, 1995.
19. Wang, T C., Cardiff, R. D., Zukerberg, L., Lees, E , Arnold, A., and Schmidt, E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (Lond.), 369: 669-671, 1994.
20. Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., and Weinberg, R. A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell, 82: 621-630, 1995.
21. Fantl, V., Stamp, G., Andrews, A., Rosewell, I., and Dickson, C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev., 9. 2364-2372, 1995.
22. Musgrove, E. A., Hamilton, J. A., Lee, C. S., Sweeney, K. J., Watts, C. K., and Sutherland, R. L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol., 13: 3577-3587, 1993.
23. Motokura, T., and Arnold, A. Cyclin D and oncogenesis. Curr. Opin. Genet. Dev., 3: 5-10, 1993.
24. 1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA, 91: 8022-8026, 1994.
25. Horsfall, D. J., Tilley, W. D., Orell, S. R., Marshall, V R., and Cant, E L. Relationship between ploidy and steroid hormone receptors in primary. Br. J. Cancer, 53: 23-28, 1986.
26. Xiong, Y , Connolly, T., Futcher, B., and Beach, D. Human D-type cyclin. Cell, 65: 691-699, 1991.
27. Misrahi, M., Atger, M., d'Auriol, L., Loosfelt, H., Meriel, C , Fridlansky, F., Guiochon, M. A., Galibert, F., and Milgrom, E. Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA Biochem. Biophys. Res. Commun., 143: 740-748, 1987.
28. Mattei, M. G., Krust, A., Stropp, U., Mattei, J. F., and Chambon, P. Assignment of the human progesterone receptor to the q22 band of chromosome 11. Hum. Genet., 78: 96-97, 1988.
29. Schoenfeld, D. The asymptomatic properties of nonparametric test for comparing survival distribution. Biometrika, 68: 316-319, 1981.
30. Borg, A., Sigurdsson, H., Clark, G. M., Femo, M., Fuqua, S. A , Olsson, H., Killander, D., and McGurie, W. L. Association of INT2/ HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br. J. Cancer, 63: 136-142, 1991.
31. Berns, E. M., Klijn. J. G., van Staveren, I. L., Portengen, H., Noordegraaf, E., and Foekens, J. A. Prevalence of amplification of the oncogenes c-myc, HER-2/neu, and int-2 in 1000 human breast tumours: correlation with steroid receptors. Eur. J. Cancer, 28: 697-700, 1992.
32. Tsuda, H., Hirohashi, S., Shimosato, Y., Hirota, T , Tsugane, S., Yamamoto, H., Miyajima, N., Toyoshima, K., Yamamoto, T., Yokota, J., Yoshida, T., Sakamoto, H., Terada, M., and Sugimura, T. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units. hst-I/int-2 and c-erbB2lear-I. Cancer Res., 49: 3104-3108, 1989.
33. Adnane, J., Gaudray, P., Simon, M. P , Simony-Lafontaine, J., Jeanteur, P., and Theillet, C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene, 4: 1389-1395, 1989.
34. Tang, R. P., Kacinski, B., Validire, P., Beuvon, F , Sastre, X., Benoit, P., dela Rochefordiere, A., Mosseri, V., Pouillart, P., and Scholl, S. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J. Cell. Biochem , 44: 189-198, 1990.
35. Fantl, V., Richards, M. A., Smith. R., Lammie, G. A., Johnstone, G., Allen, D., Gregory, W., Peters, G., Dickson, C., and Barnes, D. M. Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur. J. Cancer., 26. 423-429, 1990.
36. Schuuring, E., Verhoeven, E., van Tinteren, H., Peterse, J. L., Nunnink, B., Thunnissen, F. B., Devilee, P., Cornelisse, C J., van de Vijver, M. J., Mooi, W. J., and Michalides, R. J. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res., 52: 5229-5234, 1992.
37. Gaffey, M. J., Fnerson, H , Jr., and Williams, M. E Chromosome 11q13, c-erbB2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations. Mod. Pathol., 6: 654-659, 1993.
38. Henry, J. A., Hennessy, C., Levett, D. L., Lennard, T. W., Westley, B. R., and May, F. E. Int-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-erbB2 and c-myc. Int. J. Cancer, 53: 774-780, 1993.
39. Berns, P. M., Klijn. J. G., Staveren. I. L., Smid, M., Look, M. P., and Foekens, J. A. Distinct gene alterations as related with prognosis in human primary breast cancer. Breast Cancer Res. Treat., 32 (Suppl.): 92, 1994.
40. Berns, E., Foekens, J., van Staveren, I., van Putten, W., de Koning, H., Portengen, H., and Klijn, J. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene (Amst.), 159: 11-18, 1995.
41. Karlseder, J., Zeillinger, R., Schneeberger, C., Czerwenka, K., Speiser, P , Kubista, E., Birnbaum, D., Gaudray, P., and Theillet, C Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes & Cancer, 9: 42-48, 1994.
42. Dickson, C., Deed, R., Dixon, M., and Peters, G. The structure and function of the int-2 oncogene. Prog. Growth Factor Res., 1. 123-132, 1989.
43. Delli Bovi, P., Curatola, A. M., Kern, F. G., Greco, A., Ittmann, M., and Basilico, C. An oncogene isolated by transfection of Kaposi's sarcoma DNA encodes a growth factor that is a member of the FGF family. Cell, 50: 729-737, 1987.
44. Tsujimoto, Y., Yunis, J., Onorato, S. L., Erikson, J., Nowell, P. C., and Croce, C. M. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science (Washington DC), 224: 1403-1406, 1984.
45. Williams, M E., and Swerdlow, S. H. Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement. Ann. Oncol., 5 (Suppl. 1): 71-73, 1994.
46. Pavy, J J., Descotes, F., and Adessi, G L. HER-2/neu oncogene: what does amplification mean? Br. J. Cancer, 68: 214-215, 1993.
47. Pauletti, G., Godolphin, W., Press, M. F., and Slamun, D J. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene, in press, 1996.
48. Hui, R., Cornish, A. L., McClelland, R. A., Robertson, J. F., Blamey, R. W., Musgrove, E. A., Nicholson, R. I , and Sutherland, R. L. Cyclin D1 and estrogen receptor gene expression are positively correlated in primary breast cancer. Clin Cancer Res., 2: 923-928, 1996.